



May 7, 2018

Pharmacy Announcement

## **Prior Authorization Required for Mavyret™ and Vosevi®**

Effective April 16, 2018, Mavyret™ and Vosevi® require prior authorization to maintain consistency with the hepatitis C class of medications. Until the Drug Use Review (DUR) Board reviews these medications for criteria, the initial criteria will be that the medication is being used according to Food and Drug Administration (FDA) approved indications. Vosevi® is also currently listed as non-preferred on the Preferred Drug List (PDL) and will need to meet non-preferred criteria as well.